{"id":{"repo_id":"msu","oai_identifier":"oai:d.lib.msu.edu:etd_52686"},"canonical_url":"https://search.ndltd.org/etd/msu/oai:d.lib.msu.edu:etd_52686","repository":{"repo_id":"msu","name":"Michigan State University","base_url":"https://d.lib.msu.edu/oai"},"display":{"title":"Investigation of MicroRNA-10b as a Potential Target for Glioblastoma Nanotherapy","abstract":"Thesis (Ph.D.)--Michigan State University. Biomedical Engineering - Doctor of Philosophy, 2025","abstract_html":"Thesis (Ph.D.)--Michigan State University. Biomedical Engineering - Doctor of Philosophy, 2025","abstract_has_math":false,"creators":["Kim, Bryan Doyun"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Moore, Anna","Kim, Taeho","Hardy, Jonathan","Schmidt, Jens"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025","date_published":"2025","updated_at":"2026-11-18T18:59:26Z","subjects":["Biomedical engineering","Nanotechnology"],"languages":["eng"],"rights":["In Copyright"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52686","local:Kim_grad.msu_0128D_21655"],"render_values":[{"text":"etd:52686","href":null,"code":true},{"text":"local:Kim_grad.msu_0128D_21655","href":null,"code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://doi.org/doi:10.25335/s0b3-dh27","outbound_label":"DOI","outbound_source":"dc:identifier","record_url":"https://doi.org/doi:10.25335/s0b3-dh27","record_label":"Repository record","record_kind":"doi","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_52686","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Moore, Anna","Kim, Taeho","Hardy, Jonathan","Schmidt, Jens"]},{"key":"dc:creator","label":"Author","values":["Kim, Bryan Doyun"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025"]},{"key":"dc:relation","label":"Dc Relation","values":["Electronic Theses & Dissertations"]},{"key":"dc:type","label":"Dc Type","values":["text","Electronic dissertations"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Biomedical engineering","Nanotechnology"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["eng"]},{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["etd:52686","local:Kim_grad.msu_0128D_21655","https://doi.org/doi:10.25335/s0b3-dh27"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["Thesis (Ph.D.)--Michigan State University. Biomedical Engineering - Doctor of Philosophy, 2025","Glioblastoma is the most common and aggressive primary malignancy of the central nervous system with poor survival. Despite continued efforts, the development of therapeutics for glioblastoma is complicated by molecular heterogeneity and the presence of blood-brain barrier, which even in its disrupted form presents a challenge for drug delivery. Notably, microRNA-10b has recently been identified as a highly expressed biomarker in glioblastomas, a characteristic associated with tumorigenic pathways in metastatic cancers, whereas normal brain tissues are virtually devoid of microRNA-10b. The mounting body of evidence has shown that microRNA-10b is implicated in tumor cell invasion, migration, and, most importantly, viability. Inhibiting microRNA-10b with antisense oligonucleotides in glioblastoma cells disrupts various tumorigenesis pathways and ultimately results in cell death, revealing its importance for tumor cell survival. Delivery of naked oligonucleotides represents a challenge due to their inability to cross the cell membrane due to charge-charge repulsion, short half-life and digestion by nucleases, entrapment in endosomes, off-target effects, and activation of immune responses. To this end, we have developed a nanotherapy, termed MN-anti-miR10b, to ensure effective delivery of antisense microRNA-10b oligonucleotides to inhibit miR-10b and elicit cytotoxic effects in glioblastoma. MN-anti-miR10b consists of an iron oxide magnetic nanoparticle core covered with cross-linked dextran conjugated with Cy5.5 fluorophores and therapeutic anti-miR-10b locked-nucleic acid antagomirs. The superparamagnetic iron oxide core provides magnetic resonance imaging contrast while Cy5.5 is detectable by optical imaging modalities in vivo, thus enabling image guided therapy. The project described here begins with demonstrating in vitro that MN-anti-miR10b inhibits microRNA-10b, reduces migration and invasion, and induces cell death in glioblastoma cell lines. Following these studies, we show with multiple in vivo and ex vivo imaging modalities that MN-anti-miR10b is able to pass the disrupted blood-brain barrier and accumulate in the orthotopic glioblastoma tumor region. Ultimately, the studies culminate to show that MN-anti-miR10b and TTX-MC138, the commercialized and clinically tested analog, confer survival benefits in mice bearing orthotopic glioblastoma tumors. These studies demonstrate the efficacy of MN-anti-miR10b as a therapeutic against glioblastoma and make a case for the rapid translation for use in the clinic in GBM patients.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf","1 online resource (122 p.) : ill."]},{"key":"dc:title","label":"Title","values":["Investigation of MicroRNA-10b as a Potential Target for Glioblastoma Nanotherapy"]}]}],"canonical_facts":{"dc:contributor":["Moore, Anna","Kim, Taeho","Hardy, Jonathan","Schmidt, Jens"],"dc:creator":["Kim, Bryan Doyun"],"dc:date":["2025"],"dc:description":["Thesis (Ph.D.)--Michigan State University. Biomedical Engineering - Doctor of Philosophy, 2025","Glioblastoma is the most common and aggressive primary malignancy of the central nervous system with poor survival. Despite continued efforts, the development of therapeutics for glioblastoma is complicated by molecular heterogeneity and the presence of blood-brain barrier, which even in its disrupted form presents a challenge for drug delivery. Notably, microRNA-10b has recently been identified as a highly expressed biomarker in glioblastomas, a characteristic associated with tumorigenic pathways in metastatic cancers, whereas normal brain tissues are virtually devoid of microRNA-10b. The mounting body of evidence has shown that microRNA-10b is implicated in tumor cell invasion, migration, and, most importantly, viability. Inhibiting microRNA-10b with antisense oligonucleotides in glioblastoma cells disrupts various tumorigenesis pathways and ultimately results in cell death, revealing its importance for tumor cell survival. Delivery of naked oligonucleotides represents a challenge due to their inability to cross the cell membrane due to charge-charge repulsion, short half-life and digestion by nucleases, entrapment in endosomes, off-target effects, and activation of immune responses. To this end, we have developed a nanotherapy, termed MN-anti-miR10b, to ensure effective delivery of antisense microRNA-10b oligonucleotides to inhibit miR-10b and elicit cytotoxic effects in glioblastoma. MN-anti-miR10b consists of an iron oxide magnetic nanoparticle core covered with cross-linked dextran conjugated with Cy5.5 fluorophores and therapeutic anti-miR-10b locked-nucleic acid antagomirs. The superparamagnetic iron oxide core provides magnetic resonance imaging contrast while Cy5.5 is detectable by optical imaging modalities in vivo, thus enabling image guided therapy. The project described here begins with demonstrating in vitro that MN-anti-miR10b inhibits microRNA-10b, reduces migration and invasion, and induces cell death in glioblastoma cell lines. Following these studies, we show with multiple in vivo and ex vivo imaging modalities that MN-anti-miR10b is able to pass the disrupted blood-brain barrier and accumulate in the orthotopic glioblastoma tumor region. Ultimately, the studies culminate to show that MN-anti-miR10b and TTX-MC138, the commercialized and clinically tested analog, confer survival benefits in mice bearing orthotopic glioblastoma tumors. These studies demonstrate the efficacy of MN-anti-miR10b as a therapeutic against glioblastoma and make a case for the rapid translation for use in the clinic in GBM patients.","Description based on online resource. Title from PDF t.p. (Michigan State University Fedora Repository, viewed ).","Includes bibliographical references."],"dc:format":["application/pdf","1 online resource (122 p.) : ill."],"dc:identifier":["etd:52686","local:Kim_grad.msu_0128D_21655","https://doi.org/doi:10.25335/s0b3-dh27"],"dc:language":["eng"],"dc:relation":["Electronic Theses & Dissertations"],"dc:rights":["In Copyright"],"dc:subject":["Biomedical engineering","Nanotechnology"],"dc:title":["Investigation of MicroRNA-10b as a Potential Target for Glioblastoma Nanotherapy"],"dc:type":["text","Electronic dissertations"]},"updated_at":"2026-11-18T18:59:26Z"}